Medicare Rx Becomes Law Dec. 8; Firms Analyzing Bill, PR Approaches
Executive Summary
The signing of the Medicare prescription drug benefit legislation presents drug companies with the happy challenge of communicating the potential impact of the bill to investors without triggering a political backlash
You may also be interested in...
BIO Top Priority Is Medicare Reimbursement Negotiations, Chairman Says
Negotiating appropriate Medicare reimbursement rates is one of the Biotechnology Industry Organization's top priorities over the next two years, Alkermes CEO and BIO Chairman Richard Pops said Feb. 25
BIO Top Priority Is Medicare Reimbursement Negotiations, Chairman Says
Negotiating appropriate Medicare reimbursement rates is one of the Biotechnology Industry Organization's top priorities over the next two years, Alkermes CEO and BIO Chairman Richard Pops said Feb. 25
Novartis Applauds Medicare Rx Pilot; Overall Bill “Somewhat Negative”
Novartis hopes to see some immediate benefit from the Medicare prescription drug law from a Centers for Medicare & Medicaid Services pilot program to study expanded coverage of oral chemotherapy drugs